Purpose

The purpose of the study is to assess the experiences of individuals with acromegaly who are receiving injections as part of their treatment regimen. Another objective of the study is to compare the patients' perception with their doctors' perceptions. The answers are important to help researchers and physicians understand what it is really like to take currently available treatments so that they can make efforts to improve patients' healthcare experiences, reduce treatment burden and, ultimately, improve patient's quality of life.

Condition

Eligibility

Eligible Ages
Between 18 Years and 94 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age >=18 years-old and <95 years-old - Patient self-reported acromegaly diagnosis which will be further confirmed by a knowledge screening based on current medications and doses - Currently on injectable Somatostatin analogues (SSA), Sandostatin® LAR or Somatuline® Depot, for >=12 months - Have not had a change in dosage of their acromegaly treatment at the time of or since their last office visit - Have seen their treating acromegaly physician within the past 12 +/-2 months NOTE: This timeframe allows two additional months for scheduling an appointment with their physician, since most patients should see their acromegaly physician at least once every 12 months - Ability to read and understand English - Live and receive acromegaly treatments in the US - Willing to provide signed informed consent

Exclusion Criteria

  • Previous or current participant in Mycapssa® (octreotide capsules) trial - Use of Pegvisomant (Somavert®) monotherapy - Use of Pasireotide (Signifor®)

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross-Sectional

Arm Groups

ArmDescriptionAssigned Intervention
Patients Patients diagnosed with acromegaly and currently taking long-acting somatostatin analogues for treatment.
Physicians Physicians for those treating the patients enrolled in the study.

More Details

Status
Completed
Sponsor
Tulane University

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.